Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Apollo Therapeutics
Biotech
Apollo $15M bet on IL-18 antibody pays off with ph. 2 eczema win
Apollo’s $15 million bet on Avalo’s anti-IL-18 monoclonal antibody appears to have paid off after the candidate aced a dermatitis trial.
James Waldron
Sep 16, 2025 9:50am
Apollo takes off with $226M series C for hub-and-spoke R&D model
Sep 6, 2023 10:24am
Avalo looks to LIGHT as lead asset fails phase 2, shares fall
Jun 26, 2023 4:05pm
Apollo lands inflammatory antibody from Avalo for $90M biobucks
Aug 1, 2022 10:36am
Apollo Therapeutics to go 'full throttle' with $145M financing
Jun 17, 2021 12:01am
